Litigation Details for Picone v. Shire U.S. Inc. (Indirect Purchaser Antitrust Class Action) (D. Mass. 2016)

Picone v. Shire U.S. Inc. (Indirect Purchaser Antitrust Class Action) (D. Mass. 2016)

Docket		Date Filed	2016-11-23
Court	District Court, D. Massachusetts	Date Terminated	2022-01-26
Cause	28:1332 Diversity-Property Damage	Assigned To
Jury Demand	Plaintiff	Referred To
Patents	6,287,599; 6,811,794
Link to Docket	External link to docket

Details for Picone v. Shire U.S. Inc. (Indirect Purchaser Antitrust Class Action) (D. Mass. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
0000-00-00				External link to document
2016-11-22	1		method-of-use patent, and U.S. Patent Nos. 6,287,599 (‘599 Patent) and 6,811,794 (‘794 Patent), which cover…Shire’s Intuniv patent portfolio consists of U.S. Patent Nos. 5,854,290 (‘290 Patent), which is a now-invalidated…applied a patent procurement strategy known as “evergreening.” “Evergreened” patents are patents not on …method-of-use patent (‘290 Patent) of guanfacine hydrochloride and two extended release formulation patents (‘599…-of-Use Patent 57. Shire asserted all three (3) patents, including the ‘290 Patent, against	External link to document
2017-10-31	102		5,854,290 (the ’290 patent), 6,287,599 (the ’599 patent), and 6,811,794 (the ’794 patent), the terms of which…5,854,290 (the ’290 patent), 6,287,599 (the ’599 patent), and 6,811,794 (the ’794 patent), the terms of which…that ’290 patent was a method-of-use patent. Shire denies any characterization of those patents, and denies…under three patents that covered Intuniv and that were listed in the Orange Book: U.S. Patent Nos. 5,854,290…under three patents that cover Intuniv and that were listed in the Orange Book: U.S. Patent Nos. 5,854,290	External link to document